Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume - PubMed (original) (raw)
. 2009 Sep 15;66(6):533-9.
doi: 10.1016/j.biopsych.2009.05.006. Epub 2009 Jun 25.
Collaborators, Affiliations
- PMID: 19559402
- DOI: 10.1016/j.biopsych.2009.05.006
Free article
Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume
James M Stone et al. Biol Psychiatry. 2009.
Free article
Abstract
Background: The glutamate model of schizophrenia proposes that altered glutamatergic neurotransmission is fundamental to the development of the disorder. In addition, its potential to mediate neurotoxicity raises the possibility that glutamate dysfunction could underlie neuroanatomic changes in schizophrenia. Here we determine whether changes in brain glutamate are present in subjects at ultra high risk of developing psychosis and whether these changes are related to reductions in cortical gray matter volume.
Methods: Twenty-seven individuals with an at-risk mental state and a group of 27 healthy volunteers underwent proton magnetic resonance spectroscopy and volumetric proton magnetic resonance imaging using a 3-Tesla scanner. Glutamate and glutamine levels were measured in anterior cingulate, left hippocampus, and left thalamus. These measures were then related to cortical gray matter volume.
Results: At-risk mental state (ARMS) subjects had significantly lower levels of glutamate than control subjects in the thalamus (p < .05) but higher glutamine in the anterior cingulate (p < .05). Within the ARMS group, the level of thalamic glutamate was directly correlated with gray matter volume in the medial temporal cortex and insula (p < .01).
Conclusions: This study provides the first evidence that brain glutamate function is perturbed in people with prodromal signs of schizophrenia and that glutamatergic dysfunction is associated with a reduction in gray matter volume in brain regions thought to be critical to the pathogenesis of the disorder. These findings support the hypothesis that drugs affecting the glutamate system may be of benefit in the early stages of psychotic illness.
Comment in
- Cortical development and glutamatergic dysregulation in schizophrenia.
Sawa A. Sawa A. Biol Psychiatry. 2009 Sep 15;66(6):530-2. doi: 10.1016/j.biopsych.2009.07.016. Biol Psychiatry. 2009. PMID: 19712774 Free PMC article. No abstract available.
Similar articles
- Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.
Fusar-Poli P, Stone JM, Broome MR, Valli I, Mechelli A, McLean MA, Lythgoe DJ, O'Gorman RL, Barker GJ, McGuire PK. Fusar-Poli P, et al. Arch Gen Psychiatry. 2011 Sep;68(9):881-90. doi: 10.1001/archgenpsychiatry.2011.46. Epub 2011 May 2. Arch Gen Psychiatry. 2011. PMID: 21536967 - Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis.
Valli I, Stone J, Mechelli A, Bhattacharyya S, Raffin M, Allen P, Fusar-Poli P, Lythgoe D, O'Gorman R, Seal M, McGuire P. Valli I, et al. Biol Psychiatry. 2011 Jan 1;69(1):97-9. doi: 10.1016/j.biopsych.2010.08.033. Epub 2010 Oct 30. Biol Psychiatry. 2011. PMID: 21035785 - Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.
Tandon N, Bolo NR, Sanghavi K, Mathew IT, Francis AN, Stanley JA, Keshavan MS. Tandon N, et al. Schizophr Res. 2013 Aug;148(1-3):59-66. doi: 10.1016/j.schres.2013.05.024. Epub 2013 Jun 20. Schizophr Res. 2013. PMID: 23791389 - What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.
Abbott C, Bustillo J. Abbott C, et al. Curr Opin Psychiatry. 2006 Mar;19(2):135-9. doi: 10.1097/01.yco.0000214337.29378.cd. Curr Opin Psychiatry. 2006. PMID: 16612192 Review. - Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence.
Treen D, Batlle S, Mollà L, Forcadell E, Chamorro J, Bulbena A, Perez V. Treen D, et al. Schizophr Res. 2016 Mar;171(1-3):166-75. doi: 10.1016/j.schres.2016.01.005. Epub 2016 Jan 21. Schizophr Res. 2016. PMID: 26803691 Review.
Cited by
- Molecular and micro-architectural mapping of gray matter alterations in psychosis.
García-San-Martín N, Bethlehem RAI, Mihalik A, Seidlitz J, Sebenius I, Alemán-Morillo C, Dorfschmidt L, Shafiei G, Ortiz-García de la Foz V, Merritt K, David A, Morgan SE, Ruiz-Veguilla M, Ayesa-Arriola R, Vázquez-Bourgon J, Alexander-Bloch A, Misic B, Bullmore ET, Suckling J, Crespo-Facorro B; Lifespan Brain Chart Consortium; Romero-García R. García-San-Martín N, et al. Mol Psychiatry. 2024 Sep 12. doi: 10.1038/s41380-024-02724-0. Online ahead of print. Mol Psychiatry. 2024. PMID: 39266711 - Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk.
Davies C, Bossong MG, Martins D, Wilson R, Appiah-Kusi E, Blest-Hopley G, Allen P, Zelaya F, Lythgoe DJ, Brammer M, Perez J, McGuire P, Bhattacharyya S. Davies C, et al. Schizophr Bull Open. 2023 Aug 14;4(1):sgad022. doi: 10.1093/schizbullopen/sgad022. eCollection 2023 Jan. Schizophr Bull Open. 2023. PMID: 39145348 Free PMC article. - Resting state and activated brain glutamate-glutamine, brain lactate, cognition, and psychopathology among males with schizophrenia: A 3 Tesla proton magnetic resonance spectroscopic (1H-MRS) study.
Singh U, Das B, Khanra S, Roy C. Singh U, et al. Indian J Psychiatry. 2024 Jan;66(1):82-89. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_621_23. Epub 2024 Jan 25. Indian J Psychiatry. 2024. PMID: 38419937 Free PMC article. - Molecular Mechanisms Provide a Landscape for Biomarker Selection for Schizophrenia and Schizoaffective Psychosis.
Fryar-Williams S, Strobel J, Clements P. Fryar-Williams S, et al. Int J Mol Sci. 2023 Oct 18;24(20):15296. doi: 10.3390/ijms242015296. Int J Mol Sci. 2023. PMID: 37894974 Free PMC article. Review. - Recent Updates on Predicting Conversion in Youth at Clinical High Risk for Psychosis.
Caballero N, Machiraju S, Diomino A, Kennedy L, Kadivar A, Cadenhead KS. Caballero N, et al. Curr Psychiatry Rep. 2023 Nov;25(11):683-698. doi: 10.1007/s11920-023-01456-2. Epub 2023 Sep 27. Curr Psychiatry Rep. 2023. PMID: 37755654 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- G0500477/MRC_/Medical Research Council/United Kingdom
- MC_U120097115/MRC_/Medical Research Council/United Kingdom
- G0700995/MRC_/Medical Research Council/United Kingdom
- G0601437/MRC_/Medical Research Council/United Kingdom
- G0501775/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical